Contributions
Abstract: P774
Type: Poster
Abstract Category: Therapy - symptomatic - Quality of life
Background: Multiple Sclerosis (MS) disease course and severity varies widely among individuals and can result in debilitating symptoms that negatively impact quality of life (QOL). The aim of this study was to investigate the impact of MS symptoms on QOL in people with progressive forms of multiple sclerosis (PMS) as compared to people with relapsing MS (RMS).
Methods: Cross-sectional patient reported data from the Pacific Northwest MS Registry were used. Patient demographics, disease history, symptoms, and the Multiple Sclerosis Impact Scale (MSIS) physical and psychological scores were examined among RMS and PMS participants who returned surveys from 2013 to 2016. Maximum Likelihood Exploratory Factor Analysis for binary variables was used to group twenty symptoms into composite factors. Multiple linear regression was applied to determine which factors were most highly correlated with quality of life indicators among the RMS and PMS cohorts.
Results: For the RMS cohort (n=1,298), symptoms clustered into 4 factors: pain and sensory problems, dysphasia/speech problems and immobility, sexual and bladder/bowel dysfunction, and cognitive/psychological impairment. Among this group, pain and sensory problems had the most influence on the physical score (Relative Risk (RR) =9.88, p< .001) and cognitive/psychological impairment had most influence on the psychological score (RR=11.02, p< .001). For those with PMS (n=794), the symptom factors were pain and sensory problems, dysphasia/speech problems and visual loss, and bladder/bowel dysfunction and spasticity. Among the PMS cohort, bladder/bowel dysfunction and spasticity had the most influence on the physical score (RR=10.07, p< .001) and pain and sensory problems had most influence on the psychological score (RR=9.88, p< .001).
Conclusion: The results demonstrated that certain symptom factors affect the psychological and physical dimensions of QOL differently among RMS and PMS. While the psychological score was most highly correlated with the sensory and pain factor for PMS, the strongest influence on the psychological score for RMS was cognitive/psychological impairment. The physical score for the PMS group was most correlated with bladder/bowel dysfunction and spasticity, while pain and sensory problems were most influential for the RMS cohort. Future studies will attempt to elucidate underlying physiological or pathophysiological features that contribute to the symptom clusters derived from factor analysis.
Disclosure:
Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner, and Lindsay Lucas have nothing to disclose.
Stanley Cohan serves on steering committees and advisory boards for Biogen, Novartis, Sanofi-Genzyme, Genentech, and Mallinckrodt, receives research support from Biogen, Novartis, Sanofi-Genzyme, Roche, Opexa, and Mallinckrodt, receives speaking honoraria from Biogen, Novartis, Sanofi-Genzyme and Acorda; received support for air travel, lodging and meals from Biogen, Novartis, and Sanofi-Genzyme.
Abstract: P774
Type: Poster
Abstract Category: Therapy - symptomatic - Quality of life
Background: Multiple Sclerosis (MS) disease course and severity varies widely among individuals and can result in debilitating symptoms that negatively impact quality of life (QOL). The aim of this study was to investigate the impact of MS symptoms on QOL in people with progressive forms of multiple sclerosis (PMS) as compared to people with relapsing MS (RMS).
Methods: Cross-sectional patient reported data from the Pacific Northwest MS Registry were used. Patient demographics, disease history, symptoms, and the Multiple Sclerosis Impact Scale (MSIS) physical and psychological scores were examined among RMS and PMS participants who returned surveys from 2013 to 2016. Maximum Likelihood Exploratory Factor Analysis for binary variables was used to group twenty symptoms into composite factors. Multiple linear regression was applied to determine which factors were most highly correlated with quality of life indicators among the RMS and PMS cohorts.
Results: For the RMS cohort (n=1,298), symptoms clustered into 4 factors: pain and sensory problems, dysphasia/speech problems and immobility, sexual and bladder/bowel dysfunction, and cognitive/psychological impairment. Among this group, pain and sensory problems had the most influence on the physical score (Relative Risk (RR) =9.88, p< .001) and cognitive/psychological impairment had most influence on the psychological score (RR=11.02, p< .001). For those with PMS (n=794), the symptom factors were pain and sensory problems, dysphasia/speech problems and visual loss, and bladder/bowel dysfunction and spasticity. Among the PMS cohort, bladder/bowel dysfunction and spasticity had the most influence on the physical score (RR=10.07, p< .001) and pain and sensory problems had most influence on the psychological score (RR=9.88, p< .001).
Conclusion: The results demonstrated that certain symptom factors affect the psychological and physical dimensions of QOL differently among RMS and PMS. While the psychological score was most highly correlated with the sensory and pain factor for PMS, the strongest influence on the psychological score for RMS was cognitive/psychological impairment. The physical score for the PMS group was most correlated with bladder/bowel dysfunction and spasticity, while pain and sensory problems were most influential for the RMS cohort. Future studies will attempt to elucidate underlying physiological or pathophysiological features that contribute to the symptom clusters derived from factor analysis.
Disclosure:
Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner, and Lindsay Lucas have nothing to disclose.
Stanley Cohan serves on steering committees and advisory boards for Biogen, Novartis, Sanofi-Genzyme, Genentech, and Mallinckrodt, receives research support from Biogen, Novartis, Sanofi-Genzyme, Roche, Opexa, and Mallinckrodt, receives speaking honoraria from Biogen, Novartis, Sanofi-Genzyme and Acorda; received support for air travel, lodging and meals from Biogen, Novartis, and Sanofi-Genzyme.